Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 1(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07368959Phase 3Recruiting

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Role: lead

NCT06041256Phase 1Completed

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

Role: lead

NCT06630169Phase 2Active Not Recruiting

Study of Cryopreserved AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Role: lead

NCT05309135Phase 1Completed

A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction

Role: lead

All 4 trials loaded